Novo Introduces New Type 2 Medication
Novo Nordisk Pharmaceuticals has introduced a new oral antidiabetic agent called Prandin (repaglinide). The medication is intended for people with type 2 diabetes, who are unable to satisfactorily control their hyperglycemia through diet and exercise. It can also be used in combination with metformin, which works with Prandin to control blood sugars.
Prandin stimulates the beta cells in the pancreas to secrete more insulin. It is taken orally as a tablet at mealtimes and works quickly and for a very short period of time. This helps patients manage their glucose load during meals, a key factor in the control of type 2 diabetes.
Although Prandin shows promise, it is not for everyone. Wendell Cheatham, MD, medical director of Novo Nordisk Pharmaceuticals, Inc., explains, "For many individuals with type 2 diabetes, insulin is still the appropriate therapy." He also notes that Prandin is not intended for type 1 patients, as it cannot restore their beta cell function.
Prandin does interact with some drugs that treat fungal and bacterial infections and troglitazone (a diabetes pill). Prandin may also cause low-glucose reactions, particularly if used with other drugs that lower glucose levels. Studies are currently underway to evaluate use of Prandin in combination with other drugs.Click Here To View Or Post Comments